Mice Model Market Research Report and Outlook by 2028

The mice model market is projected to expand from US$ 1,705.70 million in 2022 to US$ 2,340.90 million by 2028, reflecting a compound annual growth rate (CAGR) of 5.4% during this period.

The increasing application of mice models in the fields of virology and infectious diseases, along with the growing demand for personalized medicine, is driving the growth of this market. Additionally, advancements in gene editing technologies are anticipated to be a significant trend influencing the mice model market in the coming years. However, stringent regulations and ethical considerations regarding the use of animals in research pose challenges to market expansion.

For over a century, researchers have utilized animals to replicate human diseases, with mice being particularly advantageous due to their genetic similarities to humans, sharing over 80% of identical genetic material. A mice model refers to a laboratory mouse specifically used to investigate various aspects of human physiology or disease. While several model organisms exist, mice are favored for their mammalian characteristics and susceptibility to many human diseases. Numerous mice models have been developed through selective breeding and genetic engineering to target specific human ailments. The application of mice models in disease research has led to significant medical advancements, as their genomic similarities and comparable disease pathophysiology to humans make them invaluable for research and drug testing.

Mice models play a crucial role in studying the pathogenesis of infectious diseases and in the preclinical assessment of vaccines and therapies against various human pathogens. The use of genetically defined inbred strains, humanized mice, and gene knockout mice has allowed researchers to explore how pathogens induce diseases, the influence of specific host genes on disease progression, and potential targets for prevention or treatment of various infectious agents. With the rise of new infectious diseases, animal models have become essential for understanding disease mechanisms and developing therapeutic strategies. Mice with human immune system xenografts have been instrumental in studying the pathogenesis of numerous infectious agents, including Plasmodium falciparum (malaria), Mycobacterium tuberculosis, dengue virus, and influenza virus. These models have also been pivotal in HIV research, facilitating the analysis of viral and host factors that enhance viral replication, the interactions between HIV and the host immune response, and the testing of therapeutic strategies aimed at controlling or curing HIV infection. Overall, mice models are indispensable for investigating the mechanisms of infectious disease pathogenesis and serve as platforms for evaluating potential vaccines and therapies.

Over the last century, significant progress in vaccine development, antibiotics, antivirals, and infection control measures has greatly alleviated the public health burden of infectious diseases. Nevertheless, the incidence of contagious viral diseases has risen. In the last twenty years, there have been notable outbreaks of COVID-19 caused by SARS-CoV in 2002, MERS-CoV in 2012, and SARS-CoV-2 in 2019. The current SARS-CoV-2 variant is considerably more severe than its predecessor and has affected millions across over 213 countries. The COVID-19 pandemic has underscored the necessity of animal models for studying the disease's pathology and developing effective treatments. Beyond coronaviruses, mice models are recognized as the premier small animal models for studying hepatitis B virus (HBV), hepatitis C virus (HCV), Zika virus, and cytomegalovirus (CMV). According to the World Health Organization (WHO), infectious diseases account for over 17 million deaths annually. In the past two decades, more than 30 new infectious diseases have emerged, with UNAIDS reporting that 38 million individuals were living with HIV by the end of 2019. The increasing prevalence of infectious diseases is a key driver of the mice model market.

The mice model market is categorized by type, service, technology, indication, end user, application, and mode. The market is divided into segments including inbred mice, outbred mice, genetically engineered mice, hybrid mice, surgically modified mice, and spontaneous mutant mice. The inbred mice segment is expected to hold the largest market share from 2022 to 2028.

Opportunities in the Mice Model Market

Humanized mice models are utilized in basic research, safety assessments for large molecule therapeutics, simulation of human-specific infectious diseases, and efficacy testing of immunotherapy approaches. These models express human proteins in cells and tissues while exhibiting variability in mouse proteins. Humanized mice are commonly employed to investigate cancer genetics, autoimmune diseases, regenerative medicine, human hematopoiesis, infectious diseases, transplantation, and autoimmunity. They enhance the translational value of preclinical research by providing insights into disease pathways. Recent models also reflect aspects of hematopoiesis, natural immunity, neurobiology, and molecular signaling pathways that affect disease pathobiology. Overall, humanized mice models facilitate low-cost, high-throughput studies of infections or degenerative processes in natural pathogen-host cells, allowing for the examination of disease transmission and eradication.

Humanized mice models, which have been xenografted with human cells or engineered to express human genes, are extensively used to elucidate human physiology and the etiology of human-specific infections. Their advantages, including small size, rapid reproductive cycles, ease of handling, and increased genomic similarity to humans, make them invaluable in biomedical research for developing therapeutics. These models have been particularly crucial in the design and development of vaccines and antibody-based therapies for COVID-19, providing deeper insights into the infection and the effectiveness of antiviral treatments. Given these factors, the use of humanized mice models is expected to continue growing, further contributing to the expansion of the mice model market.

Key organizations such as the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), Indian Council of Medical Research (ICMR), Occupational Safety and Health Administration (OSHA), Mutant Mouse Regional Resource Center (MMRRC), Food and Drug Administration (FDA), Canadian Council on Animal Care (CCAC), Centers for Personalized Medicine (CPM), and the Organization for Economic Co-operation and Development (OECD) are among the primary and secondary sources referenced in the preparation of the report on the mice model market.